Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Global Cardiovascular Drugs Market 2009-2024

Published by: Visiongain

Published: Jun. 30, 2009 - 132 Pages


Table of Contents


1 Executive Summary

1.1 Aims of This Report

1.2 Chapter Overview

2 Cardiovascular Disease: An Overview

2.1 Financial Cost

2.2 Types of Cardiovascular and Cerebrovascular Disease

2.2.1 Ischaemic Heart Disease
2.2.2 Stroke

2.2.3 Acute Myocardial Infarction

2.2.4 Other Disorders

2.3 Risk Factors
2.4 Prevalence

2.4.1 Ischaemic Heart Disease Remains the World's Leading Cause of Death
2.4.2 Hypertensive Heart Disease on the Rise

3 Therapeutic Categories

3.1 Platelet Aggregation Inhibitors

3.1.1 Glycoprotein Inhibitors
3.1.2 COX Inhibitors and Aspirin

3.1.3 Thienopyridines

3.2 Anticoagulants
3.2.1 Heparins
3.2.2 Vitamin K Antagonists and Warfarin

3.2.3 Combined Therapy

3.3 Nitrates
3.4 Thromobolytics and Fibrinolytics

3.4.1 Streptokinase and Urokinase
3.4.2 Tissue Plasminogen Activators (t-PA)

3.4.3 Other Thrombolytic Agents

3.5 Cardiac Glycosides
3.6 Anti-Arrhythmic Agents

3.7 Prevention of Disease

3.7.1 Antihypertensives
3.7.2 Lipid-Lowering Treatments

4 Global Market 2009-2024

4.1 Key Findings

4.2 Leading Companies

4.3 Forecast for the Overall Cardiovascular Market, 2009-2024

4.4 The Market for Acute Cardiovascular Therapeutics, 2009-2024

4.5 The Future of Blockbusters in the Market

4.6 Overview of the Market

5 Platelet Aggregation Inhibitors, 2009-2024

5.1 Key Findings

5.2 Platelet Aggregation Inhibitors Market, 2009-2024

5.3 High Revenues

5.4 Top Product Plavix

5.4.1 Generic Competition Set to Strike
5.4.2 Branded Competition: Marketed and in the Pipeline

5.5 Otsuka Pharmaceutical's Pletal
5.5.1 Pletal Facing Several Abbreviated New Drug Applications
5.6 Boehringer Ingelheim's Asanantin
5.6.1 Aiming for Higher Revenues
5.7 Aspirin Cardio
5.7.1 OTC Treatments for the Prevention of Cardiovascular Disease?

5.8 The Future of Platelet Aggregation Inhibitors
6 Anticoagulants, 2009-2024

6.1 Key Findings

6.2 Total Anticoagulant Market, 2009-2024

6.3 Heparins Market, 2009-2024

6.4 Lovenox Leads the Market

6.4.1 Competition for Lovenox
6.5 Fragmin
6.5.1 Life Cycle Management and Competition
6.6 Fraxiparine
6.7 Market Share for Heparins, 2009, 2014, 2019 and 2024

6.8 Vitamin K Antagonists Market, 2009-2024

6.8.1 Leading Product Coumadin
6.8.2 Generic Competition for Warfarin

7 Nitrates, 2009-2024

7.1 Key Findings

7.2 Nitrates Market, 2009-2024

7.3 The Future of Nitrates

8 Fibrinolytics, 2009-2024

8.1 Key Findings

8.2 Fibrinolytics, 2009-2024

8.3 Activase: Leading the Category

8.3.1 Competition and the Treatment Window
8.4 Second-Generation Drug Metalyse: Aiming for the Top?
8.4.1 Mode of Administration May Give Metalyse the Edge
8.4.2 ASSENT and TROICA Studies: A Mixed Message

9 Other Product Categories, 2009-2024

9.1 Cerebral and Peripheral Therapeutics

9.1.1 New Products in the Pipeline
9.2 The Future of Anti-Arrhythmic Agents
9.2.1 Thin Pipeline and Safety Scares
9.3 Cardiac Glycosides: Low Revenues
9.3.1 Digitalis: Alleviating Symptoms or Ineffective Therapy?
10 Preventive Therapeutics, 2009-2024

10.1 Key Findings

10.2 Antihypertensives

10.2.1 Forecast for the Overall Antihypertensive Market, 2009-2024
10.2.2 Angiotensin II Antagonists Lead the Market

10.2.3 Generic Threat

10.2.4 Overall Assessment of the Market

10.3 Lipid-Lowering Therapeutics, 2009-2024
10.3.1 Forecast for the Overall Lipid Lowering Market, 2009-2024
10.3.2 Statins: A Success Story So Far

10.4 High Revenues
11 Geographical Breakdown of the Market

11.1 USA

11.2 Europe

11.3 Emerging Markets

11.3.1 China
11.3.2 India

12 SWOT Analysis of the Market

12.1 Principal Drivers

12.1.1 Increasing Prevalence of Disease Drives the Market
12.1.2 High Economic Cost of Disease

12.1.3 Risk Factors: Management Rather than Cure

12.1.4 Switching to OTC

12.1.5 Novel Therapeutics Poised to Meet Needs in the Patient Population

12.2 Principal Restraints
12.2.1 The Threat of Generic Products
12.2.2 Downward Cost Pressures

12.2.3 Buyer's Market?

12.2.4 Maturation of the Overall Market May Limit Growth

12.2.5 Antihypertensives: Is the Market Maturing?

12.2.6 Challenges to the Statins Industry

12.3 Concluding Remarks on the Future of the Market
13 Expert Opinions

13.1 Professor Jeremy Pearson

13.1.1 The Future of Stem Cells in the Treatment of Cardiovascular Disorders
13.1.2 Time Frame for Research and Development

13.1.3 Current Challenges for This Type of Therapeutics

13.2 Dr Mariola Söhngen
13.2.1 Unmet Needs for Patients Suffering from Ischaemic Strokes
13.2.2 Trends in Research and Development

13.2.3 Limitations of Anti-Clotting Drugs: New Developments

13.3 Dr Josh Reece
13.3.1 The Future of Stem Cells in the Treatment of Cardiovascular Disorders
13.3.2 Stem Cells: Niche or Mainstream?

13.3.3 Osiris Therapeutics' Prochymal

14 Pipelines and Future Trends

14.1 Gene Therapy: A Growing Area of Research

14.1.1 Potential Therapeutic Areas
14.1.2 Public Acceptance of Gene Therapy

14.2 Stem Cells: High Potential?
14.2.1 Osiris Therapeutics
14.2.2 ReNeuron

14.3 Treatment Windows and New Opportunities
14.4 Novel Antithrombotic Drugs: Limitations in the Existing Market

14.4.1 Servier's Terutroban
14.4.2 AstraZeneca's Brilinta

14.4.3 Schering-Plough's Protara

14.4.4 Schering-Plough's SCH 530348

14.5 Long-Term Oral Anticoagulants
15 Conclusions

15.1 High Revenues

15.2 Impending Patent Expiries

15.3 Expanding Market

15.4 Rehabilitation on the Rise

15.5 Summary

List of Tables

Table 2.1 Leading Causes of Death World Wide, 2004 and 2030

Table 3.1 Antihypertensive Drugs, Their Effects and Side Effects

Table 3.2 Factors Influencing Plasma Lipid Levels

Table 4.1 Leading Companies in the Cardiovascular Therapeutic Market, World Sales ($m) and Market Share (%), 2008

Table 4.2 Cardiovascular Market, World Sales ($m), 2009-2024

Table 4.3 Acute Therapeutics by Category, World Sales ($m) and Market Share (%), 2009 and 2014

Table 4.4 Key Products in the Cardiovascular Market, World Sales ($m) and Market Share (%), 2008

Table 5.1 Platelet Aggregation Inhibitors, World Sales ($m), 2008-2014

Table 5.2 Platelet Aggregation Inhibitors, World Sales ($m), 2009, 2014, 2019 and 2024

Table 6.1 Anticoagulants, World Sales ($m), 2008-2014

Table 6.2 Anticoagulants, World Sales ($m), 2009, 2014, 2019 and 2024

Table 6.3 Heparins, World Sales ($m), 2008-2014

Table 6.4 Heparins, World Sales ($m), 2009, 2014, 2019 and 2024

Table 6.5 Vitamin K Antagonists, World Sales ($m), 2009, 2014, 2019 and 2024

Table 7.1 Nitrates, World Sales ($m), 2008-2014

Table 7.2 Nitrates, World Sales ($m), 2009, 2014, 2019 and 2024

Table 8.1 Fibrinolytics, World Sales ($m), 2008-2014

Table 8.2 Fibrinolytics, World Sales ($m), 2009, 2014, 2019 and 2024

Table 9.1 Other Product Categories, World Sales ($m), 2008-2014

Table 9.2 Other Product Categories, World Sales ($m), 2009, 2014, 2019 and 2024

Table 10.1 Antihypertensive Market, World Sales ($m), 2008-2014

Table 10.2 Lipid-Lowering Therapeutics, World Sales ($m), 2008-2014

Table 10.3 Lipid-Lowering Therapeutics, World Sales ($m), 2009, 2014, 2019 and 2024

Table 11.1 Geographical Breakdown of the World Market, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024

Table 12.1 SWOT Analysis for the Cardiovascular Market, 2009

List of Figures

Figure 4.1 Leading Companies in the Cardiovascular Therapeutic Market, Market Share (%), 2008

Figure 4.2 Preventive vs. Acute Therapeutics, Market Share (%), 2009, 2014, 2019 and 2024

Figure 4.3 Sales ($m) for the Global Cardiovascular Market, 2008-2024

Figure 4.4 Acute Therapeutics by Category, Market Share (%), 2008

Figure 4.5 Sales ($m) for the Global Acute Cardiovascular Therapy Market, 2008-2024

Figure 5.1 Market Share (%) for the Leading Products in the Platelet Aggregation Inhibitor Market, 2008

Figure 5.2 Plavix, World Sales ($m), 2008-2024

Figure 5.3 Pletal, World Sales ($m), 2008-2024

Figure 5.4 Asanantin, World Sales ($m), 2009-2024

Figure 5.5 Aspirin Bayer, World Sales ($m), 2008-2024

Figure 5.6 Platelet Aggregation Inhibitors, Key Products Market Share (%), 2009, 2014, 2019 and 2024

Figure 6.1 Anticoagulants, World Sales ($m), 2008-2024

Figure 6.2 Heparins, World Sales ($m), 2008-2024

Figure 6.3 Anticoagulants, Market Share (%), 2008

Figure 6.4 Lovenox, World Sales ($m), 2008-2024

Figure 6.5 Fragmin and Fraxiparine, World Sales ($m), 2008-2024

Figure 6.6 Heparins, Market Share (%), 2009, 2014, 2019 and 2024

Figure 6.7 Vitamin K Antagonists, World Sales ($m), 2009-2024

Figure 6.8 Vitamin K Antagonists, Market Share (%), 2008

Figure 6.9 Vitamin K Inhibitors, Market Share (%), 2009, 2014, 2019 and 2024

Figure 7.1 Nitrates, World Sales ($m), 2008-2024

Figure 8.1 Activase, World Sales ($m), 2008-2024

Figure 8.2 Metalyse, World Sales ($m), 2008-2024

Figure 8.3 Key Fibrinolytics, Market Share (%), 2009, 2014, 2019 and 2024

Figure 9.1 Other Product Categories, World Sales ($m), 2009, 2014, 2019 and 2024

Figure 10.1 Antihypertensives, World Sales ($m), 2008-2024

Figure 10.2 Market Share (%) for the Various Types of Antihypertensives, 2008

Figure 10.3 World Sales ($m) for Statins and Non-Statin Lipid-Lowering Therapeutics, 2008-2024

Figure 10.4 Market Share (%) for Cholesterol Lowering Therapeutics, 2008

Figure 10.5 Types of Statins, World Sales ($m), 2008

Figure 10.6 Preventive and Acute Therapeutics, Market Share (%), 2008

Figure 11.1 Geographical Breakdown of the World Market, Market Share (%), 2008

Figure 11.2 Market Share (%) for Key Countries, 2009, 2014, 2019 and 2024

Figure 11.3 Market Share (%) for the European Market, 2009, 2014, 2019 and 2024

Figure 11.4 Geographical Areas Market Share (%), 2009, 2014, 2019 and 2024



Abstract

Cardiovascular disorders are leading causes of death worldwide. Cardiovascular therapeutics form a central part of the global pharmaceutical market, with a wide range of treatments, including leading blockbusters. As the patient population grows and cardiovascular diseases become more prevalent, cardiovascular drugs have the potential for continued sales growth in both mature and emerging markets. Our new pharma report - Global Cardiovascular Drugs Market 2009-2024 - explains how, showing you where the opportunities for growth will lie from 2009 onwards.

Predictions state that total revenues in the cardiovascular disorders market will increase steadily from 2009. This report reviews commercial prospects for therapeutics directly related to cardiovascular incidents, agents such as platelet aggregation inhibitors, anticoagulants and fibrinolytics in particular. We include preventive therapeutics - such as antihypertensives and statins - in the overall analysis, even although they are not the main focus of this report.

The years 2011 to 2015 will mark a period of high volatility in the cardiovascular market as key products - including blockbusters Plavix and Lovenox - face patent expiry. What types of therapeutic agent will enter the market from 2009 onwards, and what are their sales prospects? Where do the main opportunities lie, and what are the threats in this market? What are the principal market drivers and restraints? This report will provide you with the analytical information that you need to understand current trends and future prospects in this market area, covering those and other questions. In particular, we discuss commercial prospects for the following products in detail, including future sales values:
  • Platelet aggregation inhibitors
  • Anticoagulant drugs
  • Nitrates
  • Fibrinolytics.
Comprehensive analysis of the cardiovascular market area

Global Cardiovascular Drugs Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 60 tables and figures and three full interviews with experts. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Why you should buy Global Cardiovascular Drugs Market 2009-2024

Through buying this report you will receive the following benefits:
  • You will receive a review of the existing market for cardiovascular disorder therapeutics
  • You will receive overall revenue forecasts from 2009 to 2024, at whole market and sub-market levels for the sector
  • You will find out where leading products and companies are heading, with detailed sales forecasts from 2009 to 2024
  • You will receive forecast revenues for leading geographical markets
  • You will receive expert opinions from original research interviews
  • You will receive well-informed analyses of market drivers and restraints, including SWOT analysis for the cardiovascular sector
  • You will receive important pipeline information, seeing how present R&D is shaping the future of the cardiovascular market.


Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009